Patents by Inventor Ulrich Weigl

Ulrich Weigl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061781
    Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 4, 2021
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Patent number: 10844035
    Abstract: The present disclosure relates to a cannabidiol compound and compositions thereof and processes for preparing the compound and compositions. The processes include an acid-catalyzed reaction of a suitably selected and substituted di-bromo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dibromo-cannabidiol compound or derivative thereof. The dibromo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: November 24, 2020
    Assignee: PURISYS LLC
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Patent number: 10626120
    Abstract: The present disclosure relates to N-demethylation of a compound containing a tertiary N-methylamine, including for example a morphinan alkaloid, in a continuous flow system. In particular, the present disclosure relates to N-demethylation of oxymorphone-3,14-diacetate or 14-hydroxymorphinone-3,14-diacetate using highly active catalytic palladium (0) in a continuous flow system under elevated temperature and pressure condition. The methodology can be utilized towards the synthesis of noroxymorphone via aerobic palladium-catalyzed continuous flow N-demethylation.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 21, 2020
    Assignee: Noramco, LLC
    Inventors: Dominique Roberge, Petteri Elsner, Christian Oliver Kappe, Bernhard Gutmann, Ulrich Weigl, Douglas Phillip Cox
  • Publication number: 20190330221
    Abstract: The present disclosure relates to N-demethylation of a compound containing a tertiary N-methylamine, including for example a morphinan alkaloid, in a continuous flow system. In particular, the present disclosure relates to N-demethylation of oxymorphone-3,14-diacetate or 14-hydroxymorphinone-3,14-diacetate using highly active catalytic palladium (0) in a continuous flow system under elevated temperature and pressure condition. The methodology can be utilized towards the synthesis of noroxymorphone via aerobic palladium-catalyzed continuous flow N-demethylation.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 31, 2019
    Inventors: Dominique Roberge, Petteri Elsner, Christian Oliver Kappe, Bernhard Gutmann, Ulrich Weigl, Douglas Phillip Cox
  • Publication number: 20190127389
    Abstract: The present invention relates to processes useful in the preparation of morphine analogs and derivatives, such as naltrexone, naloxone and nalbuphine and intermediates in the synthesis of said morphine analogs and derivatives. In a particular example, the process begins with for example oxymorphone, oxycodone, 14-hydroxycodeinone or 14-hydroxymorphinone, and includes the formation of an oxazolidine-containing intermediate using catalytic oxidation.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Applicant: Noramco, Inc.
    Inventors: Christopher Oliver Kappe, Bernhard Gutmann, Ulrich Weigl, Patrick Egli, Douglas Phillip Cox, David Cantillo
  • Publication number: 20180319763
    Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: November 8, 2018
    Applicant: Noramco, Inc.
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Patent number: 10059683
    Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 28, 2018
    Assignee: Noramco, Inc.
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Patent number: 10005791
    Abstract: The present invention relates to an improved process for O-demethylating methoxy substituted morphinan-6-one derivatives using AlCl3 as a demethylating agent in a reaction-inert solvent having a water content ranging from 0.1% wt to 0.8% wt. 10.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: June 26, 2018
    Assignee: Noramco GmbH
    Inventors: Georg Ulrich Weigl, Dominik Stefan Stämpfli, Nelli Maurer
  • Publication number: 20170022211
    Abstract: The present invention relates to an improved process for O-demethylating methoxy substituted morphinan-6-one derivatives using AlCl3 as a demethylating agent in a reaction-inert solvent having a water content ranging from 0.1% wt to 0.8% wt.
    Type: Application
    Filed: April 7, 2015
    Publication date: January 26, 2017
    Applicant: CILAG AG
    Inventors: Georg Ulrich WEIGL, Dominik Stefan STÄMPFLI, Nelli MAURER
  • Publication number: 20170008869
    Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 12, 2017
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Publication number: 20170008868
    Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 12, 2017
    Inventors: Lukas Dialer, Denis Petrovic, Ulrich Weigl
  • Publication number: 20160340362
    Abstract: The present invention is directed to a process for the preparation oxymorphone freebase, comprising hydrogenation of 14-hydroxymorphinone in DMF, to yield oxymorphone freebase, preferably oxymorphone freebase of improved appearance, purity and/or yield. The present invention is further directed to oxymorphone freebase with improved impurity profile. The present invention is further directed to an HPLC or UPLC system/method for analysis of opioid compounds.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 24, 2016
    Inventors: Timothy Samuel Bailey, Paul Jonathan Nichols, Joshua S. Sasine, Ulrich Weigl, Aarti L. Joshi
  • Publication number: 20160185729
    Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Application
    Filed: July 27, 2015
    Publication date: June 30, 2016
    Inventors: Beverly L. Wolgast, Charles A. Gilson, III, Shelley Aytes, Scott A. Estrada, Dipanjan Sengupta, Brian Smith, Max Rey, Ulrich Weigl
  • Patent number: 9102627
    Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 11, 2015
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Beverly L. Wolgast, Charles A. Gilson, III, Shelley Aytes, Scott A. Estrada, Dipanjan Sengupta, Brian Smith, Max Rey, Ulrich Weigl, Heidedore Jlsabeth Rey-Papina
  • Publication number: 20150038701
    Abstract: The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2, 3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Application
    Filed: July 1, 2014
    Publication date: February 5, 2015
    Inventors: Ulrich Weigl, Frank Porstmann, Christoph Straessler, Lars Ulmer, Ulf Koetz
  • Patent number: 8946207
    Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 3, 2015
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Beverly L. Wolgast, Charles A. Gilson, III, Shelley Aytes, Scott A. Estrada, Dipanjan Sengupta, Brian Smith, Ulrich Weigl, Heidedore Jlsabeth Rey-Papina
  • Patent number: 8802845
    Abstract: The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 12, 2014
    Assignee: Arena Phamaceuticals, Inc.
    Inventors: Ulrich Weigl, Frank Porstmann, Christoph Straessler, Lars Ulmer, Ulf Koetz
  • Patent number: 8501935
    Abstract: The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: August 6, 2013
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Ulrich Weigl, Frank Porstmann, Christoph Straessler, Lars Ulmer, Ulf Koetz
  • Publication number: 20130178620
    Abstract: The present invention provides processes and intermediates for the preparation of 3-benzazepines and salts thereof which can be useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 11, 2013
    Inventors: Beverly L. Wolgast, CHARLES A. GILSON, III, SHELLEY AYTES, SCOTT A. ESTRADA, DIPANJAN SENGUPTA, BRIAN SMITH, MAX REY, ULRICH WEIGL, HEIDEDORE JLSABETH REY-PAPINA
  • Publication number: 20130178619
    Abstract: The present invention provides processes, methods and intermediates for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, salts, hydrates and crystal forms thereof which are useful as serotonin (5-HT) receptor agonists for the treatment of, for example, central nervous system disorders such as obesity.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 11, 2013
    Inventors: Ulrich Weigl, Frank Porstmann, Christoph Straessler, Lars Ulmer, Ulf Koetz